Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [21] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Hiroko Yamashita
    Akiko Ogiya
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Mitsuchika Hosoda
    Naoko Ishida
    Rie Horii
    Kieko Yamazaki
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Breast Cancer, 2016, 23 : 830 - 843
  • [22] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [23] Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer
    Yamashita, Hiroko
    Ogiya, Akiko
    Shien, Tadahiko
    Horimoto, Yoshiya
    Masuda, Norikazu
    Inao, Touko
    Osako, Tomofumi
    Takahashi, Masato
    Endo, Yumi
    Hosoda, Mitsuchika
    Ishida, Naoko
    Horii, Rie
    Yamazaki, Kieko
    Miyoshi, Yuichiro
    Yasojima, Hiroyuki
    Tomioka, Nobumoto
    BREAST CANCER, 2016, 23 (06) : 830 - 843
  • [24] The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer
    Rojas, Kristin E.
    Manasseh, Donna-Marie
    Rojas, Mary
    Mattocks, Andrea
    Portnow, Leah
    Kantharia, Sarah
    Zelenko, Natalie
    Giuliano, Christina
    Borgen, Patrick, I
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 79 - 83
  • [25] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Gulisa Turashvili
    Joanne F. Chou
    Edi Brogi
    Monica Morrow
    Maura Dickler
    Larry Norton
    Clifford Hudis
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2017, 166 : 69 - 76
  • [26] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Turashvili, Gulisa
    Chou, Joanne F.
    Brogi, Edi
    Morrow, Monica
    Dickler, Maura
    Norton, Larry
    Hudis, Clifford
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 69 - 76
  • [27] Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial
    Albain, K.
    Gray, R. J.
    Sparano, J. A.
    Makower, D. F.
    Pritchard, K. I.
    Hayes, D. F.
    Geyer, C. E., Jr.
    Dees, E. C.
    Goetz, M. P.
    Olson, J. A., Jr.
    Lively, T.
    Badve, S. S.
    Saphner, T. J.
    Wagner, L. I.
    Whelan, T. J.
    Ellis, M. J.
    Paik, S.
    Wood, W. C.
    Ravdin, P. M.
    Keane, M. M.
    Gomez, H. L.
    Reddy, P. S.
    Goggins, T. F.
    Mayer, I. A.
    Brufsky, A. M.
    Toppmeyer, D. L.
    Kaklamani, V. G.
    Berenberg, J. L.
    Abrams, J.
    Sledge, G. W., Jr.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
    Seitz, K.
    Goossens, C.
    Huebner, H.
    Gass, P.
    Uhrig, S.
    Heindl, F.
    Emons, J.
    Ruebner, M.
    Anetsberger, D.
    Hartmann, A.
    Beckmann, M. W.
    Erber, R.
    Hack, C. C.
    Fasching, P. A.
    Haeberle, L.
    ESMO OPEN, 2024, 9 (11)
  • [29] Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer
    Department of Radiology, Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul
    05505, Korea, Republic of
    Clin. Imaging, 1600, (131-137): : 131 - 137
  • [30] Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer
    Kim, Hee Jeong
    Choi, Woo Jung
    Kim, Hak Hee
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    CLINICAL IMAGING, 2021, 75 : 131 - 137